Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US

@article{Sugimoto2013HepatocellularCT,
  title={Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US},
  author={K. Sugimoto and F. Moriyasu and K. Saito and N. Rognin and N. Kamiyama and Yoshihiro Furuichi and Y. Imai},
  journal={Liver International},
  year={2013},
  volume={33},
  pages={605 - 615}
}
  • K. Sugimoto, F. Moriyasu, +4 authors Y. Imai
  • Published 2013
  • Medicine
  • Liver International
  • Early prediction of tumour response and major adverse events (AEs), especially liver failure, in patients with hepatocellular carcinoma (HCC) is essential for maximizing the clinical benefits of sorafenib. To evaluate the usefulness of dynamic contrast‐enhanced ultrasound (DCE‐US) for the early prediction of tumour response and major AEs in HCC patients. 
    37 Citations
    Early evaluation of response to sorafenib for hepatocellular carcinoma by duplex Doppler ultrasonography

    References

    SHOWING 1-10 OF 38 REFERENCES
    Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
    • 39
    Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma
    • 25
    Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    • 183
    • Highly Influential
    Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
    • 38
    • Highly Influential
    The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy
    • M. Kudo
    • Medicine
    • Journal of gastroenterology and hepatology
    • 2010
    • 102
    Toxicity and response criteria of the Eastern Cooperative Oncology Group
    • 7,871